Bilateral Deep Brain Stimulation of the Pallidum for Myoclonus-Dystonia Due to ε-Sarcoglycan Mutations

A Pilot Study

Julie Azoulay-Zyss, MD; Emmanuel Roze, MD, PhD; Marie-Laure Welter, MD, PhD; Soledad Navarro, MD; Jérôme Yelnik, MD, PhD; Fabienne Clot, PhD; Eric Bardinet, PhD; Carine Karachi, MD, PhD; Didier Dormont, MD; Damien Galanaud, MD, PhD; Bernard Pidoux, MD, PhD; Philippe Corru, MD; Marie Vidailhet, MD*; David Grabli, MD, PhD*

Objective: To assess the efficacy of bilateral deep brain stimulation of the internal pallidum in patients with myoclonus-dystonia due to genetically proved ε-sarcoglycan (SGCE–M-D) deficiency.

Design: Patients with documented SGCE–M-D undergoing bilateral deep brain stimulation of the internal pallidum were recruited. Standardized assessments of M-D were videorecorded before surgery and 6 to 9 months and 15 to 18 months after surgery, using the movement and disability subscales of the Burke-Fahn-Marsden Dystonia Rating Scale and the Unified Myoclonus Rating Scale. The analysis was based on blinded evaluation of the recordings.

Setting: Movement disorder unit in a university hospital in Paris.

Patients: Five consecutive patients with documented SGCE–M-D.

Main Outcome Measures: Myoclonus and dystonia scores at follow-up.

Results: The median myoclonus score decreased from 76 before surgery (range, 38-116) to 10 at 6 to 9 months after surgery (range, 6-31). The median dystonia score decreased from 30.0 before surgery (range, 18.5-53.0) to 4.5 after surgery (range, 3.5-16.0). Disability was also improved and symptoms remained stable between the postoperative evaluations. No adverse effects occurred.

Conclusions: Bilateral deep brain stimulation of the internal pallidum is safe and highly effective in this homogeneous population of patients with SGCE–M-D. This therapeutic option should therefore be considered for patients with severe, drug-resistant forms of the disorder.


Inherited Myoclonus-Dystonia (M-D) is a rare movement disorder of variable severity. Myoclonus is usually the main and most disabling feature. Although genetically heterogeneous, most inherited forms of the disease are caused by mutation of the ε-sarcoglycan (SGCE) gene (OMIM #159900).\(^1,2\) In a subset of patients with M-D, severe, disabling, abnormal movements are poorly responsive to drugs and have a major effect on social interaction and daily life activities.\(^3\) Deep brain stimulation (DBS) of the internal pallidum (GPI) can be beneficial in medically intractable primary torsion dystonia,\(^4,5\) and this procedure has also been tried in isolated cases of M-D, as reviewed in 2 recent reports.\(^5,6\) Six patients with genetically proved SGCE–M-D received bilateral DBS, targeting the GPI in 5 cases\(^7,8\) and the ventral intermediate median nucleus of the thalamus in 1 case\(^9\) according to previous reports. Overall, myoclonus and dystonia improved by 60% to 90%. Four other patients with genetically undocumented M-D also experienced a fair improvement after thalamic (n = 2) or pallidal (n = 2) neurostimulation. However, the clinical evaluation was blinded in only 2 of these patients.\(^5,9\) A recent report of concomitant thalamic and pallidal DBS in a patient with SGCE–M-D suggested that the GPI might be the optimal target.\(^10\) Based on the improvement of myoclonus, tremor, and dystonia in patients with severe primary torsion dystonia included in a previous study by our team,\(^4\) we conducted a pilot study of the effect of bilateral GPI DBS on motor impairment and functional disability

Video available online at www.archneurol.com
imaging of the brain were normal.

tive. Cognitive function and findings on magnetic resonance
sodium), clonazepam, and levodopa, had been poorly effec-
tive antiepileptic drugs (such as levetiracetam and valproate
to the surgery conditions. The second evaluation was per-
formed 15 to 18 months postoperatively, during routine follow-
up. The primary end point was the improvement in the motor
end points were the improvement at 15 to 18 months and the
functional impair-
the preoperative UMRS rest and action subscore with values obtained
early postoperative during continuous neu-
rastimulation and while receiving their usual medication. Pa-
tients were then divided into 2 groups: those who reached the
improvement of myoclonus sometimes observed during short-
term testing was also used as a clue to select the best contact. The
amplitude was initially set at 25% to 30% below the threshold for the
abnormality was caused by maternal uniparental disomy of chromosome 7 (mUPD7), leading to SGCE deficiency due to maternal imprinting.\(^1\)

### METHODS

#### PATIENTS

With their written informed consent, 5 consecutive patients with severe and refractory SGCE–M–D (Table 1) were treated with bilateral GPi DBS between January 1, 2003, and December 31, 2008. Their median age at the time of surgery was 42 (range, 30-71) years. Pharmacological treatments, including the highest-tolerated doses of anticholinergics, antiepileptic drugs (such as levetiracetam and valproate sodium), clonazepam, and levodopa, had been poorly effective. Cognitive function and findings on magnetic resonance imaging of the brain were normal.

### STATISTICAL ANALYSIS

Given the small number of patients, the results were analyzed using nonparametric statistics (Friedman test followed by the Wilcoxon signed rank test for matched pairs for post hoc comparisons). We compared the preoperative BFMRs movement subscore and the preoperative UMRS rest and action subscores with values obtained 6 to 9 months after surgery. The analysis also included the comparison between the preoperative BFMRs movement subscores and the preoperative UMRS rest and action subscore with values obtained 15 to 18 months after surgery. Finally, we compared the preoperative BFMRs disability subscores with the values obtained after 6 to 9 months and 15 to 18 months of continuous stimulation. \(P < .05\) was considered to indicate statistical significance.

#### RESULTS

Bilateral GPi DBS improved M–D. With blinded assessment on standardized videotapes, the median BFMRs movement subscore decreased from 30.0 (range, 18.5-53.0) preoperatively to 4.5 (range, 3.5-16.0) 6 to 9 months

<table>
<thead>
<tr>
<th>Patient No./ Sex(^a)</th>
<th>Age at Onset/ Surgery, y</th>
<th>SGCE Gene Abnormality</th>
<th>Pharmacological Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Preoperative</td>
</tr>
<tr>
<td>1/F</td>
<td>6/71</td>
<td>c304C-&gt;T p.Arg261X</td>
<td>None</td>
</tr>
<tr>
<td>2/M(^b)</td>
<td>17/36</td>
<td>mLPD7</td>
<td>Zonisamide, 150 mg/d</td>
</tr>
<tr>
<td>3/M</td>
<td>12/30</td>
<td>c734-737delATT p.Gln245ArgfsX10</td>
<td>Zonisamide, dosage unknown</td>
</tr>
<tr>
<td>4/F</td>
<td>19/44</td>
<td>c856C-&gt;T p.Gln286X</td>
<td>Clonazepam, 2 mg/d; piracetam, 2400 mg/d</td>
</tr>
<tr>
<td>5/F</td>
<td>19/42</td>
<td>c856C-&gt;T p.Gln286X</td>
<td>Levetiracetam, 1000 mg/d; valproate sodium, 1500 mg/d; piracetam, 2400 mg/d; clonazepam 2 mg/d</td>
</tr>
</tbody>
</table>

Abbreviation: SGCE, \(\varepsilon\)-sarcoglycan.

\(^a\) Alcohol improved myoclonus in all patients.

\(^b\) Myoclonus-dystonia was caused by maternal uniparental disomy of chromosome 7 (mUPD7), leading to SGCE deficiency due to maternal imprinting.\(^1\)

### Table 1. Characteristics of the Patients

<table>
<thead>
<tr>
<th>Patient No./ Sex(^a)</th>
<th>Age at Onset/ Surgery, y</th>
<th>SGCE Gene Abnormality</th>
<th>Pharmacological Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Preoperative</td>
</tr>
<tr>
<td>1/F</td>
<td>6/71</td>
<td>c304C-&gt;T p.Arg261X</td>
<td>None</td>
</tr>
<tr>
<td>2/M(^b)</td>
<td>17/36</td>
<td>mLPD7</td>
<td>Zonisamide, 150 mg/d</td>
</tr>
<tr>
<td>3/M</td>
<td>12/30</td>
<td>c734-737delATT p.Gln245ArgfsX10</td>
<td>Zonisamide, dosage unknown</td>
</tr>
<tr>
<td>4/F</td>
<td>19/44</td>
<td>c856C-&gt;T p.Gln286X</td>
<td>Clonazepam, 2 mg/d; piracetam, 2400 mg/d</td>
</tr>
<tr>
<td>5/F</td>
<td>19/42</td>
<td>c856C-&gt;T p.Gln286X</td>
<td>Levetiracetam, 1000 mg/d; valproate sodium, 1500 mg/d; piracetam, 2400 mg/d; clonazepam 2 mg/d</td>
</tr>
</tbody>
</table>

Abbreviation: SGCE, \(\varepsilon\)-sarcoglycan.
postoperatively (P = .04, Friedman test; P = .03, Wilcoxon signed rank test for matched pairs). The median UMRS rest and action subscores also decreased significantly from 76 (range, 38-116) to 10 (range, 6-31) (P = .04, Friedman test; P = .03, Wilcoxon signed rank test for matched pairs). Overall, the median improvement was 85% (range, 70%-91%) for dystonia and 83% (range, 73%-93%) for myoclonus (Figure 1, Table 2, and the Video [available at http://www.archneurol.com]). The median BFMRS disability subscore also improved significantly from 6 (range, 5-13) at baseline to 2 (range, 2-6) after 6 to 9 months of continuous stimulation (P = .02, Friedman test; P = .03, Wilcoxon signed rank test for matched pairs) (Figure 2 and Table 2). Compared with the assessment at 6 to 9 months, the BFMRS dystonia and disability subscores and the UMRS rest and action subscores remained stable at 15 to 18 months in an open evaluation (P = .97 for dystonia and P > .99 for disability, Wilcoxon signed rank test for matched pairs) (Table 2). Monopolar settings with a frequency of 130 Hz and pulse width of 60 microseconds were used for all patients. Voltage ranged from 2.0 to 4.7 V for the right GPi and from 1.6 to 3.7 V for the left GPi (Table 3). Except for patient 2, who required additional current intensity adjustments, the stimulation settings did not need to be modified after the first month. After 15 to 18 months, 3 patients were free of drug therapy, 2 were receiving low doses of benzodiazepines, and 1 was receiving botulinum toxin injections for mild cervical dystonia (Table 1).

No hardware- or stimulation-related adverse events occurred during surgery or during the 15 to 18 months of follow-up.

Seven of the 10 therapeutic contacts were located within the sensory-motor GPi, whereas 3 contacts (2 in the right and 1 in the left GPi) were located tangentially to the GPi in the internal medullar lamina (Table 3 and Figure 3).

### Table 2. Effect of Bilateral GPi Stimulation on Dystonia, Myoclonus, and Disability

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>BFMRS Movement Subscore&lt;sup&gt;a&lt;/sup&gt;</th>
<th>UMRS, Rest and Action Subscore&lt;sup&gt;b&lt;/sup&gt;</th>
<th>BFMRS, Disability Subscore&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preop 6-9 mo 12-15 mo Improvement at 6-9 mo, %</td>
<td>Preop 6-9 mo 15-18 mo Improvement at 6-9 mo, %</td>
<td>Preop 6-9 mo 15-18 mo</td>
</tr>
<tr>
<td>1</td>
<td>53.0 16.0 16.5 70</td>
<td>116 31 36 73</td>
<td>8 6 4</td>
</tr>
<tr>
<td>2</td>
<td>18.5 5.5 6.0 70</td>
<td>76 13 20 83</td>
<td>6 2 2</td>
</tr>
<tr>
<td>3</td>
<td>30.0 4.5 5.0 85</td>
<td>38 10 8 74</td>
<td>5 2 2</td>
</tr>
<tr>
<td>4</td>
<td>25.5 3.5 2.5 86</td>
<td>70 8 6 89</td>
<td>6 2 2</td>
</tr>
<tr>
<td>5</td>
<td>35.5 3.5 2.5 91</td>
<td>86 6 8 93</td>
<td>13 2 2</td>
</tr>
</tbody>
</table>

Abbreviations: BFMRS, Burke-Fahn-Marsden Dystonia Rating Scale; GPi, internal globus pallidus; postop, postoperative; preop, preoperative; UMRS, Unified Myoclonus Rating Scale.

<sup>a</sup>Indicates the sum of individual scores for each body region and represents the severity of motor disability related to dystonia (range, 0-120; a higher score indicates more severe dystonia).

<sup>b</sup>Indicates the sum of individual scores for each body region that reflect the frequency and amplitude of myoclonus at rest and during specific actions (range, 0-288; a higher score indicates more severe myoclonus).

<sup>c</sup>Based on activities of daily living. The total score (range, 0-30; a higher score indicates poorer autonomy in activities of daily living) is the sum of individual scores for 7 activities, namely, speech, handwriting, degree of dependency for hygiene, dressing, feeding, swallowing, and walking.

Bilateral GPi DBS was successful in all 5 consecutive patients with SGCE-M-D enrolled in this pilot study. Over-
all, the median improvement was similar for myoclonus and dystonia (83% and 85%, respectively) and always exceeded 70%. This motor benefit was associated with a marked functional improvement because the BFMRS disability subscore fell by a median of 67%. To our knowledge, this is the largest published report of bilateral GPi DBS in a homogeneous population of patients with SGCE–M-D. All patients with SGCE–M-D eligible for DBS from 2003 to 2008 were enrolled in the study and underwent prospective assessment by means of blinded video-based evaluation.

The benefits were similar in the 5 patients. Even patient 1, who was 71 years old at the time of surgery and had been ill for 65 years, experienced a 73% improvement for myoclonus and 70% improvement for dystonia, indicating that GPi DBS can remain highly effective in elderly patients with a long history of disease. This does not appear to be the case in patients with primary torsion dystonia, possibly because they are more prone to musculoskeletal abnormalities than are patients with M-D, in whom the dystonia is often less pronounced than the myoclonus. This large time window for surgery is important. Indeed, patients with SGCE–M-D should not undergo the operation too early in adulthood owing to the possibility of waxing and waning symptoms or spontaneous improvement during the first 2 decades of life.2

We are aware that our design did not include a sham stimulation period and that the patients were not blinded to the stimulation condition. We therefore adopted blinded evaluation of standardized videotapes, in random order, by an independent neurologist who was unaware of the patients’ stimulation status. This approach has previously been used in only 2 recent cases.5,9 It is unlikely that the benefit experienced by our patients was related to the placebo effect because the improvement was major and long-lasting. In addition, the placebo effect was minor in controlled studies of GPI stimulation for primary dystonia.3 Another limitation was the lack of specific measurement of the quality of life. However, our results suggest that the spectacular reduction of myoclonus and dystonia in all the patients was translated in terms of disability (as assessed by the disability subscore of the BFMRS). Because the motor benefit of GPI DBS was not hampered by adverse effects, it is probable that the quality of life was improved as subjectively reported by all the patients. Overall, our results in this homogeneous group of patients with SGCE–M-D are consistent with those obtained in the few similar patients described in the literature, some of whom did not have documented mutations of the SGCE gene. In these latter reports,3,8 the myoclonus score (assessed with the UMRS) fell by 78% to 94% and the BFMRS movement subscore fell by 59% to 90% after GPI DBS; these improvements were associated with a marked functional benefit. Other case reports3,9,10 describe stimulation of the ventral intermediate median nucleus of the thalamus, but this approach mainly improved the myoclonus rather than the dystonia.

None of our patients experienced any adverse effects directly related to the surgery or to stimulation, such as dysarthria. This may be explained primarily by the absence of baseline speech dystonia in M-D. In addition,
because of the strong efficacy of GPI DBS in all the patients with pulse widths as low as 60 microseconds, we did not need to use higher values as reported in previous studies,\(^3,^4\) leading to less spread of the current to structures adjacent to the GPI, such as the corticospinal tract.

In contrast to the more variable and unpredictable outcomes reported in primary dystonia,\(^3,^5\) our findings support the safety of GPI DBS for SGCE–M-D and the consistency of the motor improvement. Together with previous reports,\(^3,^6\) these findings suggest that GPI DBS should be offered to patients whose condition is refractory to medical treatment.\(^10\) Further studies including sham stimulation are required to confirm these results and to address specific questions, such as the outcomes on quality of life and psychiatric comorbidity of SGCE–M-D. The place of GPI DBS in patients with M-D who do not have genetic disorders also remains to be determined.

Accepted for Publication: April 14, 2010.

Author Affiliations: Service de Neurologie, Groupe Hospitalier Paris Saint Joseph, Université Paris 5 (Dr Azoulay-Zyss), Fédération de Neurologie (Drs Roze, Welter, Vidailhet, and Grabli), Département de Génétique et Cytogénétique (Dr Clot), and Service de Neuroradiologie (Drs Dormont and Galanaud), Assistance Publique Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Services de Neurochirurgie (Dr Pidoux), AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre Marie Curie-Paris-6, and Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche en Sante 975, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Université Pierre Marie Curie-Paris-6, (Drs Roze, Welter, Yelnik, Bardinet, Karachi, Dormont, Galanaud, Vidailhet, and Grabli), Paris, France.

Correspondence: David Grabli, MD, PhD, Fédération de Neurologie et Unité Mixte de Recherche en Sante 975, Salpêtrière Hospital, Boulevard de l'Hôpital, 75013 Paris, France (david.grabli@psl.aphp.fr).

Authors Contributions: Study concept and design: Roze, Bardinet, Dormont, Cornu, Vidailhet, and Grabli. Acquisition of data: Roze, Welter, Navarro, Clot, Karachi, Dormont, Pidoux, Cornu, and Grabli. Analysis and interpretation of data: Azoulay-Zyss, Yelnik, Bardinet, Galanaud, Vidailhet, and Grabli. Drafting of the manuscript: Azoulay-Zyss, Roze, Yelnik, Clot, and Grabli.

Critical revision of the manuscript for important intellectual content: Welter, Navarro, Bardinet, Karachi, Dormont, Galanaud, Pidoux, Cornu, and Vidailhet. Administrative, technical, and material support: Azoulay-Zyss, Navarro, Clot, Karachi, and Galanaud. Study supervision: Vidailhet and Grabli.

Financial Disclosure: None reported.


Additional Contributions: David D. Young, PhD, checked the English in the article.

REFERENCES